Pliaglis
Commercial- Indications
- Local dermal anesthesia
Company intelligence / Profile preview
ProCertus BioPharm
Wisconsin, United Statessec.gov ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Commercial
01
Overview
ProCertus BioPharm developed topical small molecule therapeutics aimed at preventing common side effects of cancer therapy such as radiation-induced skin damage and hair loss. Its lead programs reached early clinical stages (Phase I/II), but all known trials were either terminated or withdrawn by the mid-2010s. There is no evidence of active development or commercial products as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesTopical agents
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ProCertus BioPharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProCertus BioPharm.